You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Chronic Kidney Disease 2022 – Time to Add a Third Pillar to Our Treatment Approach?

  • Authors: David Cherney, PhD, MD, FRCPC; Rajiv Agarwal, MD, MS
  • CME / ABIM MOC Released: 4/6/2022
  • Valid for credit through: 4/6/2023, 11:59 PM EST
Start Activity

Target Audience and Goal Statement

This activity is intended for cardiologists, nephrologists, and diabetologists & endocrinologists.

The goal of this activity is that the learner will be better able to discuss the availability of novel treatment options for the treatment of chronic kidney disease (CKD) shown to reduce the risk of associated complications.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Mode-of-action of emerging treatment options for CKD in type 2 diabetes (T2D) 
    • Clinical benefits of selective non-steroidal mineralocorticoid receptor antagonists (MRAs) for T2D patients with CKD


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


  • David Cherney, PhD, MD, FRCPC

    Senior Scientist
    Toronto General Hospital Research Institute
    Professor - Department of Medicine
    University of Toronto
    Clinician Scientist
    University Health Network and Mount Sinai Hospitals
    Director - Renal Physiology Laboratory
    Toronto, Canada


    Advisor or consultant for: AbbVie; AstraZeneca; Bayer; Boehringer Ingelheim-Lilly; Bristol Myers Squibb; CSL-Behring; Janssen; Maze; Merck; Mitsubishi-Tanabe; Novo-Nordisk; Prometic; Sanofi
    Grants for clinical research from: AstraZeneca; Boehringer Ingelheim-Lilly; Janssen; Merck; Novo-Nordisk; Sanofi

  • Rajiv Agarwal, MD, MS

    Professor of Medicine
    Indiana University School of Medicine
    Indianapolis, Indiana, United States


    Advisor or consultant for: Akebia Therapeutics; AstraZeneca; Bayer Healthcare Pharmaceuticals, Inc.; Boehringer Ingelheim; Chinook; Diamedica; Eli Lilly; Janssen; Lexicon; Merck & Co.; Otsuka America Pharmaceuticals; Reata; Relypsa Sanofi; Vifor Pharma


  • Rita Moreira Da Silva, PhD, MA, PharmD

    Medical Education Director, WebMD Global, LLC


    Disclosure: Rita Moreira Da Silva, PhD, MA, PharmD, has disclosed no relevant financial relationships.

Compliance Reviewer

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Disclosure: Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Chronic Kidney Disease 2022 – Time to Add a Third Pillar to Our Treatment Approach?

Authors: David Cherney, PhD, MD, FRCPC; Rajiv Agarwal, MD, MSFaculty and Disclosures

CME / ABIM MOC Released: 4/6/2022

Valid for credit through: 4/6/2023, 11:59 PM EST


Transcripción en español

Download the pdf.


« Return to: Chronic Kidney Disease 2022 – Time to Add a Third Pillar to Our Treatment Approach?
  • Print